Search

Search Constraints

You searched for: Author/Creator McDermott, David F.

Search Results

1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts: National Harbor, MD, USA. 9-13 November 2016. (8th December 2016)

2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016)

4. A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. (18th July 2017)

5. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies. Issue 15 (19th May 2016)

6. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (18th May 2015)

7. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (18th May 2015)

8. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. Issue 1 (20th September 2016)

9. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. (16th June 2022)

10. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (6th September 2018)